#United States #Elk Grove Village #Orsini #KalVista #EKTERLY

Orsini Partners with KalVista for Advanced HAE Treatment

In a significant development in the realm of rare disease therapeutics, Orsini, a recognized leader in pharmacy solutions for rare diseases, has been appointed as the specialty pharmacy partner for KalVista Pharmaceuticals regarding their notable product, EKTERLY® (sepiapterin). This groundbreaking oral therapy is designed to manage acute attacks of hereditary angioedema (HAE) in both adult and pediatric patients aged 12 and older.

Understanding Hereditary Angioedema (HAE)

Hereditary angioedema is a hereditary disorder that can lead to severe swelling episodes, affecting various body parts including the limbs, face, intestines, and throat. This condition stems from dysfunction in a protein known as the C1 inhibitor, which is crucial for regulating the immune system. While an HAE attack can be triggered by minor trauma or stress, it often occurs spontaneously without any identifiable cause. EKTERLY is administered at the onset of an episode, aiming to alleviate symptoms and shorten the duration of the swelling.

Darin DeCarlo, Orsini's Chief Commercial Officer, commented on the collaboration, highlighting, "Orsini has been a leader in HAE for over 14 years, and we are dedicated to ensuring that patients receive the support they need to navigate the daily challenges associated with this condition. Our partnership with KalVista allows us to further our mission of leaving no patient behind, adding EKTERLY to our comprehensive suite of HAE therapies."

The Role of Orsini in Rare Disease Management

Founded in 1987, Orsini has established itself as a leader in managing rare diseases and gene therapies. The company's commitment to patient care has resulted in partnerships with biopharma innovators, healthcare providers, and payors, ensuring patients can access advanced treatment options.

Orsini's exemplary service model features highly trained care teams dedicated to providing personalized support to patients, which is facilitated through their comprehensive pharmacy services that include drug distribution, clinical management, patient services, and home infusion assistance.

Accredited by numerous organizations including ACHC, The Joint Commission, URAC, and NABP, Orsini has achieved several accolades such as URAC's Rare Disease Pharmacy Center of Excellence designation and specifications for excellence in rare diseases and orphan drugs through ACHC.

As more patients turn to innovative therapies like EKTERLY, the role of pharmacies such as Orsini becomes ever more crucial in providing both access and education to patients grappling with challenging health conditions.

For further information, visit Orsini’s official website, www.orsini.com.